Adults Myelodysplastic Syndromes in Algeria: A Study by the Algerian MDS Group
Introduction: Myelodysplastic syndromes (MDS) are a group of haematological disorders, whose diagnosis is based mainly on cytological studies of blood and marrow cells and cytogenetic analysis. Moreover, national epidemiological data on MDS are very scarce, especially in Maghreb countries where the...
| Main Authors: | , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
West Asia Organization for Cancer Prevention
2023-04-01
|
| Series: | Asian Pacific Journal of Cancer Biology |
| Subjects: | |
| Online Access: | http://www.waocp.com/journal/index.php/apjcb/article/view/1010 |
| _version_ | 1797338746313506816 |
|---|---|
| author | Mohamed Amine Bekadja Pierre Fenaux Sabrina Akrouf Redhouane Ahmed-Nacer Rose-marie Hamladji Amina Bouchakour Souad Taoussi Mohand Tahar Abad Mohamed Bradai Brahim Benzineb Naima Mesli M Cheritti Z Zouaoui Mohamed Benlazar Soraya Bougherira Fatiha Grifi Hocine Ait-Ali Malika allouda Malika Djillali Khadija Djouadi Fatima Kherbache Selma Hamdi Hakim Hamouda Imene Boumeida Meriem Belhani Nadia Boudjerra Fatima Zohra Kaci Soufi Osmani Nabil Yafour Soumia Barkat Fatma Soltani Razika Nacib Mahdia Saidi Laid Touati Noureddine Lakhdari Samira Zouani Hadj Touhami Djamel Saidi Lamia Cherif Louazani Mohamed Ramaoun Cherifa Akkal Nemra Mehalhal Amina Krim Noureddine Sidimansour Zohra Ouchenane Nadia Zidani Salim Nekkal Samia Barkat Y Ouarlent Mohamed Aberkane Salah Eddine Belakehal Aissa Bachiri Samir Baghdad |
| author_facet | Mohamed Amine Bekadja Pierre Fenaux Sabrina Akrouf Redhouane Ahmed-Nacer Rose-marie Hamladji Amina Bouchakour Souad Taoussi Mohand Tahar Abad Mohamed Bradai Brahim Benzineb Naima Mesli M Cheritti Z Zouaoui Mohamed Benlazar Soraya Bougherira Fatiha Grifi Hocine Ait-Ali Malika allouda Malika Djillali Khadija Djouadi Fatima Kherbache Selma Hamdi Hakim Hamouda Imene Boumeida Meriem Belhani Nadia Boudjerra Fatima Zohra Kaci Soufi Osmani Nabil Yafour Soumia Barkat Fatma Soltani Razika Nacib Mahdia Saidi Laid Touati Noureddine Lakhdari Samira Zouani Hadj Touhami Djamel Saidi Lamia Cherif Louazani Mohamed Ramaoun Cherifa Akkal Nemra Mehalhal Amina Krim Noureddine Sidimansour Zohra Ouchenane Nadia Zidani Salim Nekkal Samia Barkat Y Ouarlent Mohamed Aberkane Salah Eddine Belakehal Aissa Bachiri Samir Baghdad |
| author_sort | Mohamed Amine Bekadja |
| collection | DOAJ |
| description | Introduction: Myelodysplastic syndromes (MDS) are a group of haematological disorders, whose diagnosis is based mainly on cytological studies of blood and marrow cells and cytogenetic analysis. Moreover, national epidemiological data on MDS are very scarce, especially in Maghreb countries where the population is on average younger than in Europe or the USA. The objective of the present study was to describe demographic and clinical features and the overall survival of patients with MDS in Algeria.
Materials and Methods: This study is retrospective and national multicenter (n=19 centres), performed between 2014 to 2019. The evaluation was performed using EPI-INFO and SPSS version 21 software. Survival data were calculated using the Kaplan-Meier method and comparison of survival curves using the Log Rank test. Univariate and multivariate analysis of survival was performed using the Cox regression method. The study has been approved by the Ethical and Scientific Council of the participating hospitals. The closing date of the study is 31/12/2019.
Results: A total of 670 patients with newly diagnosed MDS have been identified. The average number of new cases was 112/year, with an annual progression rate of 19%. Demographics show a slight female predominance (M/F of 317/353=0, 89; sex ratio F/M=1.11). The median follow-up was 29,3 months (range, 1 to 77 months). The overall median age was 69 years (range 16-96). The crude mean annual incidence rate was 0, 38 per 100,000 inhabitants aged ≥15 years old and it was 0, 17/100,000 in men and 0, 21/100,000 in women. Overall survival was 39 months. According to the IPSS score, the high-risk forms are low and their overall survival was 15 months. The rate of transformation into acute myeloid leukaemia (AML) is 32%.
Conclusion: This national epidemiological survey shows an annual progression rate of 19% and an increase in incidence from 0.007/100.000 in 2005 to 0.45/100.000 in 2019. |
| first_indexed | 2024-03-08T09:35:45Z |
| format | Article |
| id | doaj.art-5a0d9fca78854b11a57eac59027b46af |
| institution | Directory Open Access Journal |
| issn | 2538-4635 |
| language | English |
| last_indexed | 2024-03-08T09:35:45Z |
| publishDate | 2023-04-01 |
| publisher | West Asia Organization for Cancer Prevention |
| record_format | Article |
| series | Asian Pacific Journal of Cancer Biology |
| spelling | doaj.art-5a0d9fca78854b11a57eac59027b46af2024-01-30T09:38:56ZengWest Asia Organization for Cancer PreventionAsian Pacific Journal of Cancer Biology2538-46352023-04-0181212910.31557/apjcb.2023.8.1.21-291010Adults Myelodysplastic Syndromes in Algeria: A Study by the Algerian MDS GroupMohamed Amine Bekadja0Pierre Fenaux1Sabrina Akrouf2Redhouane Ahmed-Nacer3Rose-marie Hamladji4Amina Bouchakour5Souad Taoussi6Mohand Tahar Abad7Mohamed Bradai8Brahim Benzineb9Naima Mesli10M Cheritti11Z Zouaoui12Mohamed Benlazar13Soraya Bougherira14Fatiha Grifi15Hocine Ait-Ali16Malika allouda17Malika Djillali18Khadija Djouadi19Fatima Kherbache20Selma Hamdi21Hakim Hamouda22Imene Boumeida23Meriem Belhani24Nadia Boudjerra25Fatima Zohra Kaci26Soufi Osmani27Nabil Yafour28Soumia Barkat29Fatma Soltani30Razika Nacib31Mahdia Saidi32Laid Touati33Noureddine Lakhdari34Samira Zouani35Hadj Touhami36Djamel Saidi37Lamia Cherif Louazani38Mohamed Ramaoun39Cherifa Akkal40Nemra Mehalhal41Amina Krim42Noureddine Sidimansour43Zohra Ouchenane44Nadia Zidani45Salim Nekkal46Samia Barkat47Y Ouarlent48Mohamed Aberkane49Salah Eddine Belakehal50Aissa Bachiri51Samir Baghdad52Hematology and Cell Therapy Department Ehu Oran, Algeria.Hematology and Cell Therapy Department Ehu Oran, Algeria.Hematology and Cell Therapy Department Ehu Oran, Algeria.Hematology and Cell Therapy Department Ehu Oran, Algeria.Hematology and Cell Therapy Department Ehu Oran, Algeria.Hematology and Cell Therapy Department Ehu Oran, Algeria.Hematology and Cell Therapy Department Ehu Oran, Algeria.Hematology and Cell Therapy Department Ehu Oran, Algeria.Hematology and Cell Therapy Department Ehu Oran, Algeria.Hematology and Cell Therapy Department Ehu Oran, Algeria.Hematology and Cell Therapy Department Ehu Oran, Algeria.Hematology and Cell Therapy Department Ehu Oran, Algeria.Hematology and Cell Therapy Department Ehu Oran, Algeria.Hematology and Cell Therapy Department Ehu Oran, Algeria.Hematology and Cell Therapy Department Ehu Oran, Algeria.Hematology and Cell Therapy Department Ehu Oran, Algeria.Hematology and Cell Therapy Department Ehu Oran, Algeria.Hematology and Cell Therapy Department Ehu Oran, Algeria.Hematology and Cell Therapy Department Ehu Oran, Algeria.Hematology and Cell Therapy Department Ehu Oran, Algeria.Hematology and Cell Therapy Department Ehu Oran, Algeria.Hematology and Cell Therapy Department Ehu Oran, Algeria.Hematology and Cell Therapy Department Ehu Oran, Algeria.Hematology and Cell Therapy Department Ehu Oran, Algeria.Hematology and Cell Therapy Department Ehu Oran, Algeria.Hematology and Cell Therapy Department Ehu Oran, Algeria.Hematology and Cell Therapy Department Ehu Oran, Algeria.Hematology and Cell Therapy Department Ehu Oran, Algeria.Hematology and Cell Therapy Department Ehu Oran, Algeria.Hematology and Cell Therapy Department Ehu Oran, Algeria.Hematology and Cell Therapy Department Ehu Oran, Algeria.Hematology and Cell Therapy Department Ehu Oran, Algeria.Hematology and Cell Therapy Department Ehu Oran, Algeria.Hematology and Cell Therapy Department Ehu Oran, Algeria.Hematology and Cell Therapy Department Ehu Oran, Algeria.Hematology and Cell Therapy Department Ehu Oran, Algeria.Hematology and Cell Therapy Department Ehu Oran, Algeria.Hematology and Cell Therapy Department Ehu Oran, Algeria.Hematology and Cell Therapy Department Ehu Oran, Algeria.Hematology and Cell Therapy Department Ehu Oran, Algeria.Hematology and Cell Therapy Department Ehu Oran, Algeria.Hematology and Cell Therapy Department Ehu Oran, Algeria.Hematology and Cell Therapy Department Ehu Oran, Algeria.Hematology and Cell Therapy Department Ehu Oran, Algeria.Hematology and Cell Therapy Department Ehu Oran, Algeria.Hematology and Cell Therapy Department Ehu Oran, Algeria.Hematology and Cell Therapy Department Ehu Oran, Algeria.Hematology and Cell Therapy Department Ehu Oran, Algeria.Hematology and Cell Therapy Department Ehu Oran, Algeria.Hematology and Cell Therapy Department Ehu Oran, Algeria.Hematology and Cell Therapy Department Ehu Oran, Algeria.Hematology and Cell Therapy Department Ehu Oran, Algeria.Hematology and Cell Therapy Department Ehu Oran, Algeria.Introduction: Myelodysplastic syndromes (MDS) are a group of haematological disorders, whose diagnosis is based mainly on cytological studies of blood and marrow cells and cytogenetic analysis. Moreover, national epidemiological data on MDS are very scarce, especially in Maghreb countries where the population is on average younger than in Europe or the USA. The objective of the present study was to describe demographic and clinical features and the overall survival of patients with MDS in Algeria. Materials and Methods: This study is retrospective and national multicenter (n=19 centres), performed between 2014 to 2019. The evaluation was performed using EPI-INFO and SPSS version 21 software. Survival data were calculated using the Kaplan-Meier method and comparison of survival curves using the Log Rank test. Univariate and multivariate analysis of survival was performed using the Cox regression method. The study has been approved by the Ethical and Scientific Council of the participating hospitals. The closing date of the study is 31/12/2019. Results: A total of 670 patients with newly diagnosed MDS have been identified. The average number of new cases was 112/year, with an annual progression rate of 19%. Demographics show a slight female predominance (M/F of 317/353=0, 89; sex ratio F/M=1.11). The median follow-up was 29,3 months (range, 1 to 77 months). The overall median age was 69 years (range 16-96). The crude mean annual incidence rate was 0, 38 per 100,000 inhabitants aged ≥15 years old and it was 0, 17/100,000 in men and 0, 21/100,000 in women. Overall survival was 39 months. According to the IPSS score, the high-risk forms are low and their overall survival was 15 months. The rate of transformation into acute myeloid leukaemia (AML) is 32%. Conclusion: This national epidemiological survey shows an annual progression rate of 19% and an increase in incidence from 0.007/100.000 in 2005 to 0.45/100.000 in 2019.http://www.waocp.com/journal/index.php/apjcb/article/view/1010myelodysplastic syndrome, epidemiology, incidence, clinical features, overall survival, algerian population, |
| spellingShingle | Mohamed Amine Bekadja Pierre Fenaux Sabrina Akrouf Redhouane Ahmed-Nacer Rose-marie Hamladji Amina Bouchakour Souad Taoussi Mohand Tahar Abad Mohamed Bradai Brahim Benzineb Naima Mesli M Cheritti Z Zouaoui Mohamed Benlazar Soraya Bougherira Fatiha Grifi Hocine Ait-Ali Malika allouda Malika Djillali Khadija Djouadi Fatima Kherbache Selma Hamdi Hakim Hamouda Imene Boumeida Meriem Belhani Nadia Boudjerra Fatima Zohra Kaci Soufi Osmani Nabil Yafour Soumia Barkat Fatma Soltani Razika Nacib Mahdia Saidi Laid Touati Noureddine Lakhdari Samira Zouani Hadj Touhami Djamel Saidi Lamia Cherif Louazani Mohamed Ramaoun Cherifa Akkal Nemra Mehalhal Amina Krim Noureddine Sidimansour Zohra Ouchenane Nadia Zidani Salim Nekkal Samia Barkat Y Ouarlent Mohamed Aberkane Salah Eddine Belakehal Aissa Bachiri Samir Baghdad Adults Myelodysplastic Syndromes in Algeria: A Study by the Algerian MDS Group Asian Pacific Journal of Cancer Biology myelodysplastic syndrome, epidemiology, incidence, clinical features, overall survival, algerian population, |
| title | Adults Myelodysplastic Syndromes in Algeria: A Study by the Algerian MDS Group |
| title_full | Adults Myelodysplastic Syndromes in Algeria: A Study by the Algerian MDS Group |
| title_fullStr | Adults Myelodysplastic Syndromes in Algeria: A Study by the Algerian MDS Group |
| title_full_unstemmed | Adults Myelodysplastic Syndromes in Algeria: A Study by the Algerian MDS Group |
| title_short | Adults Myelodysplastic Syndromes in Algeria: A Study by the Algerian MDS Group |
| title_sort | adults myelodysplastic syndromes in algeria a study by the algerian mds group |
| topic | myelodysplastic syndrome, epidemiology, incidence, clinical features, overall survival, algerian population, |
| url | http://www.waocp.com/journal/index.php/apjcb/article/view/1010 |
| work_keys_str_mv | AT mohamedaminebekadja adultsmyelodysplasticsyndromesinalgeriaastudybythealgerianmdsgroup AT pierrefenaux adultsmyelodysplasticsyndromesinalgeriaastudybythealgerianmdsgroup AT sabrinaakrouf adultsmyelodysplasticsyndromesinalgeriaastudybythealgerianmdsgroup AT redhouaneahmednacer adultsmyelodysplasticsyndromesinalgeriaastudybythealgerianmdsgroup AT rosemariehamladji adultsmyelodysplasticsyndromesinalgeriaastudybythealgerianmdsgroup AT aminabouchakour adultsmyelodysplasticsyndromesinalgeriaastudybythealgerianmdsgroup AT souadtaoussi adultsmyelodysplasticsyndromesinalgeriaastudybythealgerianmdsgroup AT mohandtaharabad adultsmyelodysplasticsyndromesinalgeriaastudybythealgerianmdsgroup AT mohamedbradai adultsmyelodysplasticsyndromesinalgeriaastudybythealgerianmdsgroup AT brahimbenzineb adultsmyelodysplasticsyndromesinalgeriaastudybythealgerianmdsgroup AT naimamesli adultsmyelodysplasticsyndromesinalgeriaastudybythealgerianmdsgroup AT mcheritti adultsmyelodysplasticsyndromesinalgeriaastudybythealgerianmdsgroup AT zzouaoui adultsmyelodysplasticsyndromesinalgeriaastudybythealgerianmdsgroup AT mohamedbenlazar adultsmyelodysplasticsyndromesinalgeriaastudybythealgerianmdsgroup AT sorayabougherira adultsmyelodysplasticsyndromesinalgeriaastudybythealgerianmdsgroup AT fatihagrifi adultsmyelodysplasticsyndromesinalgeriaastudybythealgerianmdsgroup AT hocineaitali adultsmyelodysplasticsyndromesinalgeriaastudybythealgerianmdsgroup AT malikaallouda adultsmyelodysplasticsyndromesinalgeriaastudybythealgerianmdsgroup AT malikadjillali adultsmyelodysplasticsyndromesinalgeriaastudybythealgerianmdsgroup AT khadijadjouadi adultsmyelodysplasticsyndromesinalgeriaastudybythealgerianmdsgroup AT fatimakherbache adultsmyelodysplasticsyndromesinalgeriaastudybythealgerianmdsgroup AT selmahamdi adultsmyelodysplasticsyndromesinalgeriaastudybythealgerianmdsgroup AT hakimhamouda adultsmyelodysplasticsyndromesinalgeriaastudybythealgerianmdsgroup AT imeneboumeida adultsmyelodysplasticsyndromesinalgeriaastudybythealgerianmdsgroup AT meriembelhani adultsmyelodysplasticsyndromesinalgeriaastudybythealgerianmdsgroup AT nadiaboudjerra adultsmyelodysplasticsyndromesinalgeriaastudybythealgerianmdsgroup AT fatimazohrakaci adultsmyelodysplasticsyndromesinalgeriaastudybythealgerianmdsgroup AT soufiosmani adultsmyelodysplasticsyndromesinalgeriaastudybythealgerianmdsgroup AT nabilyafour adultsmyelodysplasticsyndromesinalgeriaastudybythealgerianmdsgroup AT soumiabarkat adultsmyelodysplasticsyndromesinalgeriaastudybythealgerianmdsgroup AT fatmasoltani adultsmyelodysplasticsyndromesinalgeriaastudybythealgerianmdsgroup AT razikanacib adultsmyelodysplasticsyndromesinalgeriaastudybythealgerianmdsgroup AT mahdiasaidi adultsmyelodysplasticsyndromesinalgeriaastudybythealgerianmdsgroup AT laidtouati adultsmyelodysplasticsyndromesinalgeriaastudybythealgerianmdsgroup AT noureddinelakhdari adultsmyelodysplasticsyndromesinalgeriaastudybythealgerianmdsgroup AT samirazouani adultsmyelodysplasticsyndromesinalgeriaastudybythealgerianmdsgroup AT hadjtouhami adultsmyelodysplasticsyndromesinalgeriaastudybythealgerianmdsgroup AT djamelsaidi adultsmyelodysplasticsyndromesinalgeriaastudybythealgerianmdsgroup AT lamiacheriflouazani adultsmyelodysplasticsyndromesinalgeriaastudybythealgerianmdsgroup AT mohamedramaoun adultsmyelodysplasticsyndromesinalgeriaastudybythealgerianmdsgroup AT cherifaakkal adultsmyelodysplasticsyndromesinalgeriaastudybythealgerianmdsgroup AT nemramehalhal adultsmyelodysplasticsyndromesinalgeriaastudybythealgerianmdsgroup AT aminakrim adultsmyelodysplasticsyndromesinalgeriaastudybythealgerianmdsgroup AT noureddinesidimansour adultsmyelodysplasticsyndromesinalgeriaastudybythealgerianmdsgroup AT zohraouchenane adultsmyelodysplasticsyndromesinalgeriaastudybythealgerianmdsgroup AT nadiazidani adultsmyelodysplasticsyndromesinalgeriaastudybythealgerianmdsgroup AT salimnekkal adultsmyelodysplasticsyndromesinalgeriaastudybythealgerianmdsgroup AT samiabarkat adultsmyelodysplasticsyndromesinalgeriaastudybythealgerianmdsgroup AT youarlent adultsmyelodysplasticsyndromesinalgeriaastudybythealgerianmdsgroup AT mohamedaberkane adultsmyelodysplasticsyndromesinalgeriaastudybythealgerianmdsgroup AT salaheddinebelakehal adultsmyelodysplasticsyndromesinalgeriaastudybythealgerianmdsgroup AT aissabachiri adultsmyelodysplasticsyndromesinalgeriaastudybythealgerianmdsgroup AT samirbaghdad adultsmyelodysplasticsyndromesinalgeriaastudybythealgerianmdsgroup |